Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine

Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2014-04, Vol.88 (5), p.1085-1091
Hauptverfasser: Folkert, Michael R., MD, PhD, Bilsky, Mark H., MD, Tom, Ashlyn K., BA, Oh, Jung Hun, PhD, Alektiar, Kaled M., MD, Laufer, Ilya, MD, Tap, William D., MD, Yamada, Yoshiya, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1091
container_issue 5
container_start_page 1085
container_title International journal of radiation oncology, biology, physics
container_volume 88
creator Folkert, Michael R., MD, PhD
Bilsky, Mark H., MD
Tom, Ashlyn K., BA
Oh, Jung Hun, PhD
Alektiar, Kaled M., MD
Laufer, Ilya, MD
Tap, William D., MD
Yamada, Yoshiya, MD
description Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade >3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.
doi_str_mv 10.1016/j.ijrobp.2013.12.042
format Article
fullrecord <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22416522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301613037206</els_id><sourcerecordid>1687674888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</originalsourceid><addsrcrecordid>eNqFkt-K1TAQxoMo7nH1DUQC3njTmqRN2t4Isuw_WFmwK3gXctLJ2dSepiapeHwH33nT7dELb4RAIPObbybzDUKvKckpoeJ9n9veu-2UM0KLnLKclOwJ2tC6arKC869P0YYUgmRFgk_QixB6QgilVfkcnbBSCCoE26Dft3PUbg8Bq7HDd-6n1TYesHEeXx0mZ7zS0bpRRegeidaOuwGyi-M7vt6rHWSXs-0S0Ebw4OIS0viz6qwLs9-BX_Va5VMlFfAniCqkY38lMRwdjveA28mO8BI9M2oI8Op4n6IvF-d3Z1fZze3l9dnHm0zzsowZ52ZLjAIDtAPFCaelUoIqxmugDaka0ZSsKaqaGUJMwzXvjFGmaNKkVMWgOEVvV10XopUhfRn0vXbjCDpKxkoqOGOJerdSk3ffZwhR7m3QMAxqBDcHSUVdiaqs6zqh5Ypq70LwYOTk7V75g6RELnbJXq52ycUuSZlMdqW0N8cK83YP3d-kP_4k4MMKQJrGDwt-aRZGDZ31S6-ds_-r8K-AHuxotRq-wQFC72Y_pklLKkNKkO2yMsvG0IIUFSOieADfmb8I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687674888</pqid></control><display><type>article</type><title>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Folkert, Michael R., MD, PhD ; Bilsky, Mark H., MD ; Tom, Ashlyn K., BA ; Oh, Jung Hun, PhD ; Alektiar, Kaled M., MD ; Laufer, Ilya, MD ; Tap, William D., MD ; Yamada, Yoshiya, MD</creator><creatorcontrib>Folkert, Michael R., MD, PhD ; Bilsky, Mark H., MD ; Tom, Ashlyn K., BA ; Oh, Jung Hun, PhD ; Alektiar, Kaled M., MD ; Laufer, Ilya, MD ; Tap, William D., MD ; Yamada, Yoshiya, MD</creatorcontrib><description>Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade &gt;3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2013.12.042</identifier><identifier>PMID: 24661662</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Dose Fractionation ; Female ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; METASTASES ; Middle Aged ; MULTIVARIATE ANALYSIS ; Neoplasm Metastasis ; PATIENTS ; Prognosis ; Proportional Hazards Models ; RADIATION DOSES ; Radiation Injuries - diagnosis ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOSENSITIVITY ; Radiosurgery - adverse effects ; Radiosurgery - methods ; RADIOTHERAPY ; Radiotherapy Dosage ; RISK ASSESSMENT ; Sarcoma - mortality ; Sarcoma - pathology ; Sarcoma - surgery ; SARCOMAS ; Spinal Neoplasms - mortality ; Spinal Neoplasms - secondary ; Spinal Neoplasms - surgery ; SURGERY ; TOXICITY ; Treatment Outcome ; VERTEBRAE</subject><ispartof>International journal of radiation oncology, biology, physics, 2014-04, Vol.88 (5), p.1085-1091</ispartof><rights>2014</rights><rights>Copyright © 2014. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</citedby><cites>FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301613037206$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24661662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22416522$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Folkert, Michael R., MD, PhD</creatorcontrib><creatorcontrib>Bilsky, Mark H., MD</creatorcontrib><creatorcontrib>Tom, Ashlyn K., BA</creatorcontrib><creatorcontrib>Oh, Jung Hun, PhD</creatorcontrib><creatorcontrib>Alektiar, Kaled M., MD</creatorcontrib><creatorcontrib>Laufer, Ilya, MD</creatorcontrib><creatorcontrib>Tap, William D., MD</creatorcontrib><creatorcontrib>Yamada, Yoshiya, MD</creatorcontrib><title>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade &gt;3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cohort Studies</subject><subject>Dose Fractionation</subject><subject>Female</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>Neoplasm Metastasis</subject><subject>PATIENTS</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>RADIATION DOSES</subject><subject>Radiation Injuries - diagnosis</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOSENSITIVITY</subject><subject>Radiosurgery - adverse effects</subject><subject>Radiosurgery - methods</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>RISK ASSESSMENT</subject><subject>Sarcoma - mortality</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - surgery</subject><subject>SARCOMAS</subject><subject>Spinal Neoplasms - mortality</subject><subject>Spinal Neoplasms - secondary</subject><subject>Spinal Neoplasms - surgery</subject><subject>SURGERY</subject><subject>TOXICITY</subject><subject>Treatment Outcome</subject><subject>VERTEBRAE</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt-K1TAQxoMo7nH1DUQC3njTmqRN2t4Isuw_WFmwK3gXctLJ2dSepiapeHwH33nT7dELb4RAIPObbybzDUKvKckpoeJ9n9veu-2UM0KLnLKclOwJ2tC6arKC869P0YYUgmRFgk_QixB6QgilVfkcnbBSCCoE26Dft3PUbg8Bq7HDd-6n1TYesHEeXx0mZ7zS0bpRRegeidaOuwGyi-M7vt6rHWSXs-0S0Ebw4OIS0viz6qwLs9-BX_Va5VMlFfAniCqkY38lMRwdjveA28mO8BI9M2oI8Op4n6IvF-d3Z1fZze3l9dnHm0zzsowZ52ZLjAIDtAPFCaelUoIqxmugDaka0ZSsKaqaGUJMwzXvjFGmaNKkVMWgOEVvV10XopUhfRn0vXbjCDpKxkoqOGOJerdSk3ffZwhR7m3QMAxqBDcHSUVdiaqs6zqh5Ypq70LwYOTk7V75g6RELnbJXq52ycUuSZlMdqW0N8cK83YP3d-kP_4k4MMKQJrGDwt-aRZGDZ31S6-ds_-r8K-AHuxotRq-wQFC72Y_pklLKkNKkO2yMsvG0IIUFSOieADfmb8I</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Folkert, Michael R., MD, PhD</creator><creator>Bilsky, Mark H., MD</creator><creator>Tom, Ashlyn K., BA</creator><creator>Oh, Jung Hun, PhD</creator><creator>Alektiar, Kaled M., MD</creator><creator>Laufer, Ilya, MD</creator><creator>Tap, William D., MD</creator><creator>Yamada, Yoshiya, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20140401</creationdate><title>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</title><author>Folkert, Michael R., MD, PhD ; Bilsky, Mark H., MD ; Tom, Ashlyn K., BA ; Oh, Jung Hun, PhD ; Alektiar, Kaled M., MD ; Laufer, Ilya, MD ; Tap, William D., MD ; Yamada, Yoshiya, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-55fb0faefe1dea50514aa61a258e19079694293782f00f95c5dffaf39013a72e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cohort Studies</topic><topic>Dose Fractionation</topic><topic>Female</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>Neoplasm Metastasis</topic><topic>PATIENTS</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>RADIATION DOSES</topic><topic>Radiation Injuries - diagnosis</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOSENSITIVITY</topic><topic>Radiosurgery - adverse effects</topic><topic>Radiosurgery - methods</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>RISK ASSESSMENT</topic><topic>Sarcoma - mortality</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - surgery</topic><topic>SARCOMAS</topic><topic>Spinal Neoplasms - mortality</topic><topic>Spinal Neoplasms - secondary</topic><topic>Spinal Neoplasms - surgery</topic><topic>SURGERY</topic><topic>TOXICITY</topic><topic>Treatment Outcome</topic><topic>VERTEBRAE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Folkert, Michael R., MD, PhD</creatorcontrib><creatorcontrib>Bilsky, Mark H., MD</creatorcontrib><creatorcontrib>Tom, Ashlyn K., BA</creatorcontrib><creatorcontrib>Oh, Jung Hun, PhD</creatorcontrib><creatorcontrib>Alektiar, Kaled M., MD</creatorcontrib><creatorcontrib>Laufer, Ilya, MD</creatorcontrib><creatorcontrib>Tap, William D., MD</creatorcontrib><creatorcontrib>Yamada, Yoshiya, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Folkert, Michael R., MD, PhD</au><au>Bilsky, Mark H., MD</au><au>Tom, Ashlyn K., BA</au><au>Oh, Jung Hun, PhD</au><au>Alektiar, Kaled M., MD</au><au>Laufer, Ilya, MD</au><au>Tap, William D., MD</au><au>Yamada, Yoshiya, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>88</volume><issue>5</issue><spage>1085</spage><epage>1091</epage><pages>1085-1091</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose Conventional radiation treatment (20-40 Gy in 5-20 fractions, 2-5 Gy per fraction) for sarcoma metastatic to the spine provides subtherapeutic doses, resulting in poor durable local control (LC) (50%-77% at 1 year). Hypofractionated (HF) and/or single-fraction (SF) image-guided stereotactic radiosurgery (IG-SRS) may provide a more effective means of managing these lesions. Methods and Materials Patients with pathologically proven high-grade sarcoma metastatic to the spine treated with HF and SF IG-SRS were included. LC and overall survival (OS) were analyzed by the use of Kaplan-Meier statistics. Univariate and multivariate analyses were performed by the use of Cox regression with competing-risks analysis; all confidence intervals are 95%. Toxicities were assessed according to Common Terminology Criteria for Adverse Events, version 4.0. Results From May 2005 to November 11, 2012, 88 patients with 120 discrete metastases received HF (3-6 fractions; median dose, 28.5 Gy; n=52, 43.3%) or SF IG-SRS (median dose, 24 Gy; n=68, 56.7%). The median follow-up time was 12.3 months. At 12 months, LC was 87.9% (confidence interval [CI], 81.3%-94.5%), OS was 60.6% (CI, 49.6%-71.6%), and median survival was 16.9 months. SF IG-SRS demonstrated superior LC to HF IG-SRS (12-month LC of 90.8% [CI, 83%-98.6%] vs 84.1% [CI, 72.9%-95.3%] P =.007) and retained significance on multivariate analysis ( P =.030, hazard ratio 0.345; CI, 0.132-0.901]. Treatment was well tolerated, with 1% acute grade 3 toxicity, 4.5% chronic grade 3 toxicity, and no grade &gt;3 toxicities. Conclusions In the largest series of metastatic sarcoma to the spine to date, IG-SRS provides excellent LC in the setting of an aggressive disease with low radiation sensitivity and poor prognosis. Single-fraction IG-SRS is associated with the highest rates of LC with minimal toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24661662</pmid><doi>10.1016/j.ijrobp.2013.12.042</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0360-3016
ispartof International journal of radiation oncology, biology, physics, 2014-04, Vol.88 (5), p.1085-1091
issn 0360-3016
1879-355X
language eng
recordid cdi_osti_scitechconnect_22416522
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Aged, 80 and over
Cohort Studies
Dose Fractionation
Female
HAZARDS
Hematology, Oncology and Palliative Medicine
Humans
Male
METASTASES
Middle Aged
MULTIVARIATE ANALYSIS
Neoplasm Metastasis
PATIENTS
Prognosis
Proportional Hazards Models
RADIATION DOSES
Radiation Injuries - diagnosis
Radiology
RADIOLOGY AND NUCLEAR MEDICINE
RADIOSENSITIVITY
Radiosurgery - adverse effects
Radiosurgery - methods
RADIOTHERAPY
Radiotherapy Dosage
RISK ASSESSMENT
Sarcoma - mortality
Sarcoma - pathology
Sarcoma - surgery
SARCOMAS
Spinal Neoplasms - mortality
Spinal Neoplasms - secondary
Spinal Neoplasms - surgery
SURGERY
TOXICITY
Treatment Outcome
VERTEBRAE
title Outcomes and Toxicity for Hypofractionated and Single-Fraction Image-Guided Stereotactic Radiosurgery for Sarcomas Metastasizing to the Spine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A49%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20and%20Toxicity%20for%20Hypofractionated%20and%20Single-Fraction%20Image-Guided%20Stereotactic%20Radiosurgery%20for%20Sarcomas%20Metastasizing%20to%20the%20Spine&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Folkert,%20Michael%20R.,%20MD,%20PhD&rft.date=2014-04-01&rft.volume=88&rft.issue=5&rft.spage=1085&rft.epage=1091&rft.pages=1085-1091&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2013.12.042&rft_dat=%3Cproquest_osti_%3E1687674888%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1687674888&rft_id=info:pmid/24661662&rft_els_id=1_s2_0_S0360301613037206&rfr_iscdi=true